AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 70 filers reported holding AUDENTES THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $75,786,000 | +350.7% | 1,266,506 | +111.5% | 0.01% | +100.0% |
| Q3 2019 | $16,817,000 | -13.5% | 598,705 | +16.6% | 0.00% | -20.0% |
| Q2 2019 | $19,436,000 | +13.5% | 513,384 | +16.9% | 0.01% | +25.0% |
| Q1 2019 | $17,130,000 | +1.9% | 439,030 | -44.3% | 0.00% | +33.3% |
| Q4 2018 | $16,818,000 | +25.8% | 788,910 | +133.7% | 0.00% | -25.0% |
| Q3 2018 | $13,365,000 | +11.1% | 337,599 | +7.2% | 0.00% | 0.0% |
| Q2 2018 | $12,034,000 | +73.9% | 314,950 | +36.8% | 0.00% | +100.0% |
| Q1 2018 | $6,919,000 | +9.5% | 230,250 | +13.9% | 0.00% | 0.0% |
| Q4 2017 | $6,316,000 | +25.9% | 202,124 | +12.9% | 0.00% | 0.0% |
| Q3 2017 | $5,016,000 | +58.2% | 179,083 | +8.0% | 0.00% | +100.0% |
| Q2 2017 | $3,171,000 | +319.4% | 165,783 | +273.2% | 0.00% | – |
| Q1 2017 | $756,000 | -3.3% | 44,420 | +3.7% | 0.00% | – |
| Q4 2016 | $782,000 | +209.1% | 42,829 | +201.0% | 0.00% | – |
| Q3 2016 | $253,000 | – | 14,229 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 1,204,615 | $37,644,219,000 | 39.61% |
| Casdin Capital, LLC | 400,000 | $12,500,000 | 3.04% |
| Opaleye Management Inc. | 210,000 | $6,652,000 | 2.13% |
| Orbimed Advisors | 4,129,638 | $129,051,000 | 1.63% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,190,516 | $37,204,000 | 1.46% |
| Redmile Group, LLC | 929,326 | $29,041,000 | 1.26% |
| Cormorant Asset Management, LP | 337,876 | $10,559,000 | 1.10% |
| Perceptive Advisors | 781,309 | $24,416,000 | 0.81% |
| Rock Springs Capital Management LP | 525,000 | $16,406,000 | 0.74% |
| Virtus ETF Advisers LLC | 11,898 | $372,000 | 0.47% |